Radiation-induced lung injury after concurrent neoadjuvant chemoradiotherapy for locally advanced breast cancer

Abstract

(2014) Radiation-induced lung injury after concurrent neoadjuvant chemoradiotherapy for locally advanced breast cancer, Acta Oncologica, 53:5, 697-701,

Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer

“…Another clinical trial studied AC with paclitaxel concurrent chemoradiotherapy and showed no serious adverse reactions during the 5-year follow-up. [ 26 ] On the other hand, Chow et al [ 27 ] used FEC sequential weekly paclitaxel concurrent neoadjuvant chemoradiotherapy, but 8 patients showed grade 3 radiation pneumonitis and 1 died from respiratory distress syndrome. Thus, the dose intensity of paclitaxel may influence adverse reactions.…”

Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer

“…Novel approaches, including radiotherapy, are needed to increase the pCR rate for LABC. Combined neoadjuvant chemoradiotherapy has been studied including neoadjuvant highdose rate brachytherapy (BRT) (13,14), but these modalities are difficult to organize and deliver effectively in the neoadjuvant setting and notably in some cases have resulted in acute radiation-induced side effects (15).…”

Response to: “Current Definition of Locally Advanced Breast Cancer”

“…The goal of the Mandilaras publication 1 was to entice readers to rethink the standard paradigm: neoadjuvant chemotherapy with or without biologic therapies, surgery, adjuvant radiation, and hormone therapy. They proposed making every attempt to improve locoregional response by exploiting treatments used in other disease sites such as radiosensitization through concurrent neoadjuvant chemotherapy and radiation, which is increasingly being evaluated 6,7 .…”